Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab in Adults Hospitalized With COVID-19 Presenting Cytokine Release Syndrome
NCT04357860Phase 2Completed
- Sponsor
- Maimónides Institute of Biomedical Research of Córdoba
- Start
- Apr 2020
- Primary completion
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sarilumab in coronavirus disease 2019 (COVID-19), cytokine release syndrome (CRS), sponsored by Maimónides Institute of Biomedical Research of Córdoba. Started Apr 2020; status: completed.
02
Drugs
sarilumab
03
Conditions
coronavirus disease 2019 (COVID-19)cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT04357860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04357860.